Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody

$Lane 1: SK-BR-3 Cells; Lane 2: A549 Cells; Lane 3: Mouse Lung; Probed with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: SK-BR-3 Cells; Lane 2: A549 Cells; Lane 3: Mouse Lung; Probed with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in LOVO cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in LOVO cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Liver tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Testis tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Testis tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Rat Brain tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Rat Brain tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Flow cytometric analysis of HepG2 cells with Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody (bsm-54281R) at a 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

Applications

WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-54281R
Product Name	Cytochrome P450 Oxidoreductase (4F7) Monoclonal Antibody
Applications	WB FCM IHC-P IF(IHC-P) IF(ICC)
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein within human Cytochrome P450 Reductase aa 1-150
Clonality	Monoclonal
Clone #	4F7
Isotype	IgG
Concentration	Lot Dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	5447
Swiss Prot	P16435
Subcellular location	Endoplasmic reticulum
Synonyms	NADPH cytochrome P450 reductase; CPR; P450R; POR; CYPOR; Cytochrome p450 Reductase
Background	Cytochrome P450 Oxidoreductase is an endoplasmic reticulum membrane oxidoreductase with a FAD-binding domain and a flavodoxin-like domain. The protein binds two cofactors, FAD and FMN, which allow it to donate electrons directly from NADPH to all microsomal P450 enzymes. Mutations in this gene have been associated with various diseases, including apparent combined P450C17 and P450C21 deficiency, amenorrhea and disordered steroidogenesis, congenital adrenal hyperplasia and Antley-Bixler syndrome. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200